eMedicine Specialties > Pediatrics: General Medicine > Endocrinology

Hypermagnesemia: Treatment & Medication

Author: Anastasios K Konstantakos, MD, Clinical Associate Surgeon, Department of Cardiovascular Surgery, Billings Clinic, Billings, Montana
Contributor Information and Disclosures

Updated: May 5, 2009

Treatment

Medical Care

  • Symptoms and signs of magnesium intoxication respond to intravenous calcium. Calcium chloride (5 mL of a 10% sol) may be administered intravenously over 30 seconds to directly antagonize the cardiac and neuromuscular effects of excess extracellular magnesium. Monitor these patients in an ICU setting and give careful attention to ECG parameters.
  • In order to promote a more sustained decrease in serum magnesium, patients with normal urine output and renal function may be treated with intravenous saline infusions and furosemide diuresis.
  • Dialysis for hypermagnesemia may be used for patients with the following:
    • Renal insufficiency
    • Severe asymptomatic hypermagnesemia (>8 mEq/L)
    • Serious cardiovascular or neuromuscular symptoms at any serum magnesium level
  • Cathartics or enemas that do not contain magnesium may be used to enhance gastrointestinal clearance of excess ingested magnesium.

Consultations

  • A nephrology consult may be obtained for refractory cases of hypermagnesemia or for patients with hypermagnesemia who require urgent dialysis.

Diet

  • Advise the patient with hypermagnesemia to discontinue oral laxatives, antacids, or other preparations that contain magnesium.

Medication

Treatment depends on the degree of hypermagnesemia and the presence of symptoms. In patients with mildly increased levels, the source of magnesium may simply be removed. In patients with higher concentrations of magnesium or severe symptoms, other treatments are necessary. Reserve calcium for patients with life-threatening symptoms, such as arrhythmias or severe respiratory depression.

Intravenous fluids

Dilution of the extracellular magnesium concentration is the rationale behind intravenous use. Fluids are used with diuretics to promote diuresis of magnesium by the kidneys.


0.9% sodium chloride (normal saline)

Isotonic fluid. Restores water and sodium chloride losses.

Adult

Pediatric

<10 kg: 100 mL/kg/d
10-20 kg: 50 mL/kg/d
>20 kg: 20 mL/kg/d

May decrease levels of lithium when administered concurrently

Fluid retention; hypernatremia, hypertonic uterus; impaired renal or cardiac function

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Caution in congestive heart failure, hypertension, edema, liver cirrhosis, renal insufficiency, and sodium toxicity

Diuretics

These agents increase renal excretion of magnesium.


Furosemide (Lasix)

Increases excretion of water by interfering with chloride-binding cotransport system, which inhibits sodium and chloride reabsorption in the ascending loop of Henle and distal renal tubule. Promotes loss of magnesium. Administer PO dose with food or milk to decrease stomach upset.

Adult

20-80 mg/dose IV; not to exceed 6 mg/kg/dose; titrate to effect

Pediatric

1 mg/kg/dose q6-12h prn; titrate to effect

Nephrotoxicity of cephalosporins increased; ototoxicity may be increased with concomitant administration of aminoglycosides; metformin decreases furosemide concentrations; furosemide interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle-relaxing effect of tubocurarine; anticoagulant activity of warfarin may be enhanced when taken concurrently; increased plasma lithium levels and toxicity are possible when taken concurrently

Documented hypersensitivity; hepatic coma, anuria, state of severe electrolyte depletion, hypokalemia, and renal failure

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Monitor serum electrolytes (eg, potassium), carbon dioxide, glucose, creatinine, uric acid, calcium, and BUN determinations during first few months of therapy and periodically thereafter; closely monitor serum potassium levels; may produce intravascular dehydration, severe hypokalemia, significant hypochloremic metabolic alkalosis, hyperuricemia, and deafness due to ototoxicity

Calcium

Calcium directly antagonizes the effects of magnesium.


Calcium chloride (10% sol)

Moderates nerve and muscle performance by regulating action potential excitation threshold. Dose expressed in calcium chloride, not elemental calcium.

Adult

2-4 mg/kg IV acutely over 10 min
2-4 mg/kg/h continuous infusion

Pediatric

20 mg/kg IV, may repeat in 10 min if necessary

Coadministration with digoxin may cause arrhythmias; with thiazides, may induce hypercalcemia; may antagonize effects of calcium channel blockers, atenolol, and sodium polystyrene sulfonate

Ventricular fibrillation not associated with hyperkalemia; digitalis toxicity, hypercalcemia, renal insufficiency, or cardiac disease

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Do not administer >50 mg/min; do not administer IM/SC
Do not administer IV calcium >30-60 mg elemental calcium/min
Rapid IV administration leads to hypotension, bradycardia, and asystole

More on Hypermagnesemia

Overview: Hypermagnesemia
Differential Diagnoses & Workup: Hypermagnesemia
Treatment & Medication: Hypermagnesemia
Follow-up: Hypermagnesemia
Multimedia: Hypermagnesemia
References
Further Reading

References

  1. Reinhart RA. Magnesium metabolism. Arch Int Med. 1988;148:2415-2420. [Medline].

  2. Musso CG. Magnesium metabolism in health and disease. Int Urol Nephrol. Mar 10 2009;[Medline].

  3. Kaze Folefack F, Stoermann Chopard C. [Magnesium metabolism disturbances]. Rev Med Suisse. Mar 7 2007;3(101):605-6, 608, 610-1. [Medline].

  4. Moe SM. Disorders involving calcium, phosphorus, and magnesium. Prim Care. Jun 2008;35(2):215-37, v-vi. [Medline].

  5. Navarro-Gonzalez JF, Mora-Fernandez C, Garcia-Perez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial. Jan-Feb 2009;22(1):37-44. [Medline].

  6. [Best Evidence] Ford AA, Wylie BJ, Waksmonski CA, Simpson LL. Maternal congenital cardiac disease: outcomes of pregnancy in a single tertiary care center. Obstet Gynecol. Oct 2008;112(4):828-33. [Medline].

  7. Corbi G, Acanfora D, Iannuzzi GL, et al. Hypermagnesemia predicts mortality in elderly with congestive heart disease: relationship with laxative and antacid use. Rejuvenation Res. Feb 2008;11(1):129-38. [Medline].

  8. Ali A, Walentik C, Mantych GJ, et al. Iatrogenic acute hypermagnesemia after total parenteral nutrition infusion mimicking septic shock syndrome: two case reports. Pediatrics. Jul 2003;112(1 Pt 1):e70-2. [Medline].

  9. Durham D, Worthley LI. Cardiac arrhythmias: diagnosis and management. The tachycardias. Crit Care Resusc. Mar 2002;4(1):35-53. [Medline].

  10. Henyan NN, Gillespie EL, White CM, et al. Impact of intravenous magnesium on post-cardiothoracic surgery atrial fibrillation and length of hospital stay: a meta-analysis. Ann Thorac Surg. Dec 2005;80(6):2402-6. [Medline].

  11. Knochel JP. Disorders of magnesium metabolism. Harrison's Principles of Internal Medicine. 1994;2:2187-2189. [Medline].

  12. Nadler JL, Rude RK. Disorders of magnesium metabolism. Clinical Disorders of Fluid and Electrolyte Metabolism. 1995;24:623-637. [Medline].

  13. Rude RK, Singer FR. Magnesium deficiency and excess. Ann Rev Med. 1981;32:245-259. [Medline].

Keywords

hypermagnesemia, magnesium, Mg, elevated serum magnesium, acute renal failure, fatal hypermagnesemia, diabetic ketoacidosis, dehydration, pregnancy-induced hypertension, renal insufficiency, eclampsia, respiratory depression, heart block, asystole, hypotension, treatment, diagnosis

Contributor Information and Disclosures

Author

Anastasios K Konstantakos, MD, Clinical Associate Surgeon, Department of Cardiovascular Surgery, Billings Clinic, Billings, Montana
Disclosure: Nothing to disclose.

Medical Editor

Phyllis W Speiser, MD, Chief of Pediatric Endocrinology, Schneider Children's Hospital; Professor of Pediatrics, New York University School of Medicine
Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London), Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece
George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Lawson-Wilkins Pediatric Endocrine Society, and Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD, Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital
Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research
Disclosure: Genentech, Inc. Honoraria Speaking and teaching; Pfizer, Inc. Honoraria Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.